Natco Pharma shares jump 5% as company files for generic cancer drug approval with USFDA
Shares of Natco Pharma jumped nearly 5% to Rs 1,569 in Friday’s intraday trade on BSE after the firm submitted a product application with the US health regulator for a generic product indicated for the treatment of metastatic non-small cell lung cancer. The company has submitted an abbreviated new drug application (ANDA) containing a paragraph…
READ MORE